

**AMENDMENTS TO THE CLAIMS**

This claim set will replace all prior versions, and listing, of the claim in the application:

Claim 1 (currently amended): A modified antiangiogenic kringle 5 peptide comprising a kringle 5 peptide and a reactive group which wherein said reactive group reacts with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds and wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups.

Claim 2 (cancelled)

Claim 3 (previously presented): The modified kringle 5 peptide of claim 1 wherein the modified peptide is reactive with blood proteins.

Claim 4 (previously presented): The modified kringle 5 peptide of claim 3, wherein the modified peptide is reactive with a thiol group on a blood protein.

Claim 5 (previously presented): The modified kringle 5 peptide of claim 1 wherein the kringle 5 peptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

Claim 6 (previously presented): The modified kringle 5 peptide of claim 1 wherein the kringle 5 peptide is selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

Claims 7-9 (cancelled)

Claim 10 (previously presented): A modified kringle 5 peptide comprising a kringle 5 peptide and a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond.

Claim 11 (previously presented): The modified kringle 5 peptide of claim 10, wherein said kringle 5 peptide is selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9.

Claim 12 (previously presented): The modified kringle 5 peptide of claim 10, wherein said kringle 5 peptide is selected from SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.

Claims 13-18 (cancelled)

Claim 19 (original): A modified kringle 5 peptide selected from the group consisting of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO:17); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO:18); NAc-Arg-Tyr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO:19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO:20); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub> (SEQ ID NO:21); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub> (SEQ ID NO:22); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:23); and (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:24).

Claim 20 (original): A modified kringle 5 peptide selected from the group consisting of: NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub> (SEQ ID NO:25); (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:26); (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:27);

NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( $\text{N}\varepsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO:28);  
(MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:29); and  
(MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:30).

Claim 21 (previously presented): A modified kringle 5 peptide selected from the group consisting of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-( $\text{N}\varepsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO:31); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO:32);  
(MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO:33);  
NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( $\text{N}\varepsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO:34);  
(MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:35);  
(MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO:36);  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-( $\text{N}\varepsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO:37);  
(MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO:38);  
(MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO:39);  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( $\text{N}\varepsilon$ -AEEA-MPA)-NH<sub>2</sub> (SEQ ID NO:40); and  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( $\text{N}\varepsilon$ -AEEAn-MPA)-NH<sub>2</sub> (SEQ ID NO:41).

**AMENDMENT TO THE SEQUENCE LISTING**

Please replace the originally filed Sequence Listing with the attached substitute Sequence Listing. SEQ ID NO: 17-41 have been added to the Sequence Listing as filed.